



Republic of Serbia  
**COMMISSION FOR PROTECTION  
OF COMPETITION**

25/IV Savska St., Belgrade  
Number: 6/0-02-363/2018-8  
Date: May 24, 2018

Published text contains protected data.  
Protected data are presented with symbol [...] or in the range that the Commission finds to be an appropriate manner of protection.

Pursuant to Article 37(2) and Article 65(5) of the Law on Protection of Competition (Official Gazette of the RS 51/09 and 95/13), and Article 2(1/6) of the Tariff on the level of compensations for activities within the competence of the Commission for Protection of Competition (Official Gazette of the RS 49/11), deciding under the notification of concentration entered under number 6/0-02-363/2018-1 of April 20, 2018, submitted by company „Teva Pharmaceutical Industries Limited“, with registered seat at the address 5 Basel Street, Petach Tikva, Israel, via procurator holder, attorney at law Danijel Stevanović from the Law Office „Moravčević Vojnović i Partneri“, 15 Dobračina St., Belgrade, on May 24, 2018, the President of the Commission for Protection of Competition enacts the following

## **DECISION**

**I** Concentration of undertakings in summary procedure **IS APPROVED** created by acquisition of control on the part of company “Teva Pharmaceutical Industries Limited“, with registered seat at the address 5 Basel Street, Petach Tikva, Israel, company number 520013954, over a part of business operations of company „PGT Healthcare“ LLP, with registered seat at the address Corporation Trust Centre, 1209 Orange Street, Wilmington, Delaware, USA, company number 4957911, relating to the production and sales of over-the-counter drugs.

**II IT IS ESTABLISHED** that the Party, company “Teva Pharmaceutical Industries Limited“, has executed payment in the amount of RSD 2,954,752.50 (in words: two million, nine hundred fifty-four thousand, seven hundred fifty-two and 50/100 dinars) on May 3, 2018, to the account of the Commission for Protection of Competition, which represents a stipulated amount of the fee as compensation for issuing decision on approval of concentration in summary procedure.